MENLO PARK, Calif., Sept. 1, 2020 /PRNewswire/ — Olive Diagnostics, a digital healthcare and diagnostic options supplier, transforms in-home urinalysis with the world’s solely practical, hands-free, non-invasive prototype: K2. K2 mounts to any bathroom, detecting urine’s molecular composition, producing safe, customized diagnostic information, immediately linked by way of cellular app.
Pee pays off!
K2 transforms an on a regular basis exercise into a personalised, handy, tech-savvy healthcare instrument; a golden alternative for traders throughout upcoming Collection A funding.
Usually, folks relieve themselves 5-7 instances on a regular basis. It is usually their first and final exercise. Checking their very own well being, figuring out potential issues, making responsive life-style modifications and looking for acceptable care will undoubtedly be most relieving of all.
“Urine is central to medicinal, well being monitoring. Present options are cumbersome, limiting monitoring evaluation or medical historical past,” stated Dr. Joseph Rosenblum, medical director, Maccabi Entrepreneurship. “Folks need handy, at-home healthcare options, passive diagnostic instruments, illness prevention, early detection, and correct intervention, particularly with rising healthcare prices and COVID.”
Conventional cup-paper-dipstick ‘options’ are cumbersome, unsanitary, inaccurate and gradual. K2’s HIPPA-GDPR-compliant information produces correct diagnostics for fast situations and long run tendencies, earlier than customers may even flush.
With preliminary funding secured and the prototype full, it is time for beta testing and extra funding. K2’s market: huge (bathroom homeowners), demographic: broad (each human), and expertise: unbelievable (assume ‘Minority Report‘ for illnesses).
K2 combines spectroscopy with highly effective AI-based analytics, detecting many well being inhibitors and life-threatening brokers; purple blood cells, protein (frequent in being pregnant preeclampsia), electrolytes (disbalance), Ketone, Glucose, Creatinine and micro organism (UTI’s); alerting customers to pre-symptomatic points, generally weeks prematurely.
“The science behind K2 is astounding; prompt molecular detection, with a transferring urine stream. It is cloud-based, to consistently broaden its record of detectable well being alerts, consumer advantages and funding worth,” stated Man Goldman, Olive’s CEO, Cofounder. “We’re excited for the subsequent progress section… lively manufacturing and, finally, into households and clinics worldwide!”
This funding alternative is flowing with potential.
Olive Diagnostics’ preliminary funding comes from Cleveland Clinic, Amgen, Israeli Innovation Authority, eHealth Ventures and personal European-American traders.
web site: www.olivek2.com
SOURCE Olive Diagnostics